Search
Denali Therapeutics Inc
DNLIAdd to Watchlist
23.310USD
-0.180-0.77%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.64BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Denali Therapeutics Inc is 8.84, ranking 52 out of 389 in the Biotechnology & Medical Research industry. The average price target is 32.00, with a high of 40.00 and a low of 24.00.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
33.933
Target Price
+45.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Denali Therapeutics Inc
DNLI
19
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Denali Therapeutics Inc's expected revenue for the next quarter?
Denali Therapeutics Inc's expected revenue is 1.15M.
What is Denali Therapeutics Inc's price target?
Analysts forecast that Denali Therapeutics Inc's price target is USD 32.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 24.00.
How have Denali Therapeutics IncDNLI's recent earnings per share performed?
The market expectation was USD -0.69, while Denali Therapeutics IncDNLI's earnings per share (EPS) for the previous quarter was USD -0.73. EPS for the next quarter is expected at USD -0.67.
What is the analyst rating for Denali Therapeutics Inc?
Based on the ratings of Denali Therapeutics Inc's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
